Navigation Links
TGen-VARI-SHC research helps predict success with cancer drugs
Date:6/14/2010

PHOENIX, Ariz. June 14, 2010 Researchers at the Translational Genomics Research Institute (TGen), the Van Andel Research Institute (VARI) and the Virginia G. Piper Cancer Center at Scottsdale Healthcare have discovered a biomarker that could help in the treatment of patients with an aggressive type of lung cancer.

Using a particular biomarker, researchers might better predict which patients with small cell lung cancer are resistant to existing drug therapies, and which ones could benefit from new therapies tailored to their specific needs, according to a scientific paper published today in the Journal of Thoracic Oncology.

"There is a need for predictive biomarkers that can aid investigators in designing future clinical trials, to help identify treatments that might be effective for these patients who most likely will be resistance to existing drug therapies, " said Dr. Glen J. Weiss, the paper's senior author and Director of Thoracic Oncology at TGen Clinical Research Services at Scottsdale Healthcare. TCRS is a partnership between TGen and Scottsdale Healthcare that helps bring new therapies quickly to patients at the Virginia G. Piper Cancer Center in Scottsdale.

Nearly 220,000 Americans are diagnosed each year with lung cancer, which is by far the leading cause of cancer death in the U.S., annually killing nearly 160,000 patients.

Of all lung cancer patients, an estimated 33,000 are diagnosed with SCLC. This is a particularly aggressive disease that usually goes undetected until it is in an advanced stage and treatment options are limited. More than 95 percent of SCLC patients eventually die from the disease.

Researchers from TGen, VARI and the Virginia G. Piper Cancer Center at Scottsdale Healthcare focused on identifying microRNAs, which are single-stranded RNA molecules that regulate how genes and proteins control cellular development. Because microRNAs are so resilient, they are relatively easy to detect in tumor tissue and blood, which is often a limitation for other biomarkers.

"VARI provided bioinformatics support assembling all the different types of data into a cohesive data set for analysis to help identify the miRNA that play a role in the survival of the lung cancer patients," said Dr. David Cherba, a VARI Bioinformatics Scientist.

Researchers profiled 34 tumor samples from patients with a median age of 69. They analyzed each tumor's microRNAs, searching for those that might be associated with cancer survival.

They identified three microRNAs associated with SCLC. But one in particular, identified as miR-92-2*, was "significantly" linked to survival, the paper said.

This microRNA could be used in two significant ways:

  • As a predictive biomarker in the development of new treatments for those SCLC tumors that prove to be de novo chemoresistant possessing properties that render them inherently resistant to existing drug therapies.

  • As prognostic biomarkers in the screening of SCLC patients and the design of clinical trials better tailored to their prognosis.

"Our results demonstrate that higher tumor miR-92a-2* levels are associated with chemoresistance and with decreased survival in SCLC patients," said the paper titled MicroRNA 92a-2*, a Biomarker Predictive for Chemoresistance and Prognostic for Survival in Small Cell Lung Cancer Patients.

This was one of the first scientific papers published since the completion of the TGen-VARI alliance and affiliation agreement, announced in February.

"The collaboration that occurred on this project highlights the synergies created by the VARI-TGen alliance," said Dr. Craig Webb, a VARI Senior Scientific Investigator.

Dr. Jeffrey Trent, President and Research Director for TGen and VARI, said the new discoveries could have profound implications for the future of medicine.

"This advanced technology is exciting because of how these microRNA biomarkers could lead to improvements for patients. Hopefully, this will translate to new treatments and improved survival," Dr. Trent said.

The next step in this research should be to attain further validation by analyzing additional independent samples, the paper concludes.


'/>"/>

Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute
Source:Eurekalert

Related medicine news :

1. New research identifies modifiable risk factors for heart disease
2. Nuvo Research announces early redemption of 5% convertible debentures
3. Researcher to track spread of disease, malware and power outages
4. UCSF Researchers Identify Regulator of Human Sperm Cells
5. Octapharma Accepting Applications for Research Grants Through March 31
6. Valentine Tailgate Party for the Girls with Festive Ideas from Beauty Research
7. New Research Shows Genes of Pregnant Women and Their Fetuses Can Increase the Risk of Preterm Labor
8. University of Maryland chemist receives Astellas Award for blindness prevention research
9. Developing a cyberinfrastructure for comparative effectiveness in cancer research
10. Women should be allowed to eat, drink during labor: Queens University researcher
11. Parkinsons disease research uncovers social barrier
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... ... , ... Like jewels in a crown, the multiple awards presented to Fayez ... Ontario’s leading day spa and one of Canada’s few accredited 5 Star Spas! ... to combine spa services with hair and beauty services and has resulted ...
(Date:5/31/2016)... ... , ... In his latest video, renowned AstroNumerologist Jesse Kalsi ... presidential candidate Donald Trump as an example, Kalsi describes the way AstroNumerology conveys ... adding numbers up,” says Kalsi. “It is about looking at each individual number, ...
(Date:5/31/2016)... Linda, CA (PRWEB) , ... May 31, 2016 , ... ... both a primary screening tool and as an orthogonal tool for RNAi hit validation. ... highly functional and specific guide RNAs—allows rapid generation of CRISPR RNA (crRNA) collections in ...
(Date:5/31/2016)... ... May 31, 2016 , ... In a recent interview on The Greenburgh ... New Rochelle, NY-based WVOX (1460 AM), leading medical insurance advocate Adria Goldman ... country’s “modern medical money maelstrom.” , During the interview with Mr. Feiner that ...
(Date:5/31/2016)... ... 2016 , ... Advertising Age has recognized SourceLink, ... the tenth consecutive year as a Top 20 Marketing Services Agency. Final results ... eighteenth in the “U.S. CRM/Direct Marketing Agency” category. , Recent investments made ...
Breaking Medicine News(10 mins):
(Date:5/31/2016)... Deutschland und GERMANTOWN, Maryland ... Referenzdatensatz von Horizon bestätigt nachgewiesene ... s   QIAGEN N.V. ... Standard: QIA) gab heute die Ergänzung seines ... und Verifizierungsdaten bekannt, die die bewährte Genauigkeit ...
(Date:5/31/2016)... , Germany and ... -- QIAGEN N.V. (NASDAQ: QGEN ... extensive package consisting of a quality control set and ... System, reinforcing the proven accuracy of its next-generation sequencing ... training for laboratories. QIAGEN has incorporated the Horizon Discovery ...
(Date:5/31/2016)... 31, 2016 Diplomat Pharmacy, Inc. (NYSE: ... conversation slated for June 7, 2016, to take a closer ... noon to 1 p.m. ET, will focus on a man ... the road to wellness. The event is ... patients and health care professionals, talking about triumphs and the ...
Breaking Medicine Technology: